ELECTREON
2.12.2021 14:02:08 CET | Business Wire | Press release
ElectReon (TASE: ELWS.TA), the leading provider of inductive in-road charging technology for commercial and passenger electric vehicles, announced the launch of the “Arena of the Future'' project in Brescia, Italy where the company has integrated its wireless technology to charge an IVECO bus and Stellantis’s Fiat Nuova 500 passenger vehicle while driving. This project is demonstrating contactless charging for a range of EVs as they drive on highways and toll roads as a potential pathway to decarbonizing long-haul transportation systems along motorway transport corridors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005493/en/
The construction and technical implementation of the 1,050-metre-long circuit equipped with ElectReon’s properarity in-road charging coils and supported by 1MW of electrical power has been successfully completed. Starting today, the “Arena of the Future” is showcasing ElectReon’s inductive EV charging technology as a technological enabler of an immediate, concrete solution to decarbonize the mobility sector. This technology, recently named one of TIME’s 100 Best Inventions of 2021 , will speed up the transition to sustainable, fully electric transport as a direct response to global requirements for greenhouse gas (GHG) emissions reductions and enhanced environmental protection policy.
The first vehicles implemented at the “Arena of the Future”, a Fiat Nuova 500 and an IVECO E-way bus, have been equipped with ElectReon’s vehicle-side technology (“receiver”) that directly transfers the energy needed to charge and travel simultaneously. The receiver-equipped vehicles have already successfully completed extensive kilometres of dynamic (in-motion) charging along the 1,050 meter circuit and ongoing testing, calibration and experimentation will continue through the length of the project. ElectReon’s technology can be adapted to any electric vehicle, from a passenger vehicle to commercial truck, creating a shared platform for a “zero emissions” mobility system at scale.
ElectReon’s participation in this project highlights their commitment to ongoing strategic collaboration with major players in the global automotive industry and demonstrates the feasibility of its wireless charging technology for a full range of applications. This is a critical milestone towards ElectReon’s mission of offering fleet customers a complete and seamless vehicle-side wireless charging solution for rapid decarbonization. ElectReon’s wireless charging technology equips governments and policymakers with a sustainable way to reduce greenhouse gas (GHG) emissions throughout the entire life cycle of electric vehicles (EVs) and offers a viable path to expedited mass EV adoption and achieving net carbon emissions throughout the entire transportation sector.
“It has been an honor collaborating with world-class partners, including automotive giants IVECO and Stellantis , to launch Italy’s first Electric Road System (ERS).” said Oren Ezer, CEO of ElectReon. “We are proud to announce the launch of the first phase of the Arena of the Future project exhibiting a toll-road’s potential transformation into a charging asset and is demonstrating the ability for all road users to utilize inductive charging technology for EVs in the future. As Europe continues to lead the shift towards electric mobility, scalable advanced charging infrastructure paves the way for convenient on-the-go charging for road users. ElectReon’s wireless charging technology enables vehicles to charge as they drive at any speed on electrified highways.”
As one of the first and only companies able to demonstrate multiple miles of in-motion wireless charging on public roads, ElectReon is currently working on various pre-commercial projects across the globe ranging from Germany , Sweden and Israel with plans of expansion into North America. Most recently, ElectReon announced the development of its wireless charging network to support 200 public buses in Tel Aviv in the company’s first fully commercial deal with one of Israel’s largest Public Transport Operators after successfully delivering on the company’s initial pilot project. ElectReon also announced the recent addition of former President of Israel, Reuven “Ruvi” Rivlin , as the company’s president to facilitate relationships with world leaders to increase EV adoption, reduce fleet emissions, and accelerate ElectReon’s global impact.
This creation is one of first examples of international collaborative innovation for “zero emissions” mobility for people and goods, which today sees the collaboration of industry and academic institutions: A35 Brebemi-Aleatica, ABB, Electreon, FIAMM Energy Technology, IVECO, IVECO Bus, Mapei, Pizzarotti, Politecnico di Milano, Prysmian, Stellantis, TIM, Roma Tre University and the University of Parma.
About ElectReon
ElectReon is the leading provider of wireless charging solutions for electric vehicles (EVs), providing end-to-end charging infrastructure and services to meet the needs and efficiency demands of shared, public and commercial fleet operators and consumers. The company’s proprietary inductive technology dynamically (while in motion) and statically (while stopped) charges EVs quickly and safely, eliminating range anxiety, lowering total costs of EV ownership, and reducing battery capacity needs—making it one of the most environmentally sustainable, scalable, and compelling charging solutions available today. ElectReon works with cities and fleet operators on a charging as a service (CaaS) platform that enables cost-effective electrification of public, commercial, and autonomous fleets for smooth and continuous operation. For more information, visit electreon.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005493/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
